Page 17 - Exact Sciences News Today

If the fund manager's calculations prove to be accurate, Tesla investors could enjoy more than sevenfold returns in less than four years. Is she right?

A company developing a rival colon cancer test, which was sued by Exact Sciences in November over alleged patent infringement, has asked for a review of the patent.

A company developing a rival colon cancer test, which was sued by Exact Sciences in November over alleged patent infringement, has asked for a review of the patent.

A company developing a rival colon cancer test, which was sued by Exact Sciences in November over alleged patent infringement, has asked for a review of the patent.

Sydney, Australia (SPX) Jan 10, 2024 - Researchers from the Department of Physics at Sao Paulo State Universitys Institute of Geosciences and Exact Sciences (IGCE-UNESP) in Rio Claro, Brazil, have made a significant stride in the field

Bar-Ilan UniversityNews, press releases, and expert sources for journalists in science, medicine & business

Small cap stocks are anticipated to rise by as much as 50% in 2024 as investors look for growth in new areas of the market.

Exact Sciences Corp. (EXAS) expects total revenue for fourth quarter to be in the range of $645.5 million-$647.5 million, an increase of 17% compared to the fourth quarter of 2022.

Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, submits next-generation Cologuard® to FDA Announces Chief Financial...

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eighteen research firms that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and fifteen have assigned a buy recommendation to the company. The average twelve-month price target […]